Use of genetic polymorphisms that associate with efficacy of treatment of inflammatory disease
Details for Australian Patent Application No. 2004283235 (hide)
International Classifications
Event Publications
13 April 2006 PCT application entered the National Phase
PCT publication WO2005/040416 Priority application(s): WO2005/040416
2 August 2007 Application Accepted
Published as AU-B-2004283235
29 November 2007 Standard Patent Sealed
28 April 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired
This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.
Legal
The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.
Next and Previous Patents/Applications
2004283241-Trans-2-enoyl-CoA reductase gene of euglena gracilis
2004283234-Use of genetic polymorphisms to predict drug-induced hepatotoxicity
IP Reporting Samples
Customised IP Reporting
IP Insider for IP Professionals
IP Monitor Professional
- Editable Word format reports
- For IP Professionals
- Multiuser